Physician profile
Stefanny Cortes
NPI 1366975708
$2,237.40
in general payments reported to CMS, 2019-2025
28 companies · $697 in 2025
The $697 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $420 · 2023: $459 · 2024: $510 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $454.65 | 2021-2025 | |
| Shield Therapeutics INC | $223.38 | 2023-2025 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $140.11 | 2021-2025 | |
| Intuitive Surgical, INC. | $132.58 | 2025 | |
| Exeltis, USA INC. | $130.11 | 2021-2025 | Slynd |
| Sumitomo Pharma America, INC. | $122.66 | 2023-2025 | Myfembree |
| Pfizer INC. | $121.29 | 2022-2025 | |
| Organon LLC | $100.85 | 2021-2025 | Jada System |
| Exact Sciences Corporation | $94.69 | 2023-2024 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $86.24 | 2021-2022 | |
| Millicent US INC | $73.60 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Abbvie INC. | $70.68 | 2022-2023 | Lo Loestrin Fe |
| Novo Nordisk INC | $69.45 | 2021-2025 | Wegovy |
| Agile Therapeutics, INC. | $50.40 | 2022-2024 | Twirla |
| Sage Therapeutics, LLC | $46.05 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $42.06 | 2025 | Zepbound |
| Astellas Pharma US INC | $38.53 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $37.70 | 2023 | Gardasil 9 |
| Myovant Sciences INC. | $33.50 | 2022 | |
| Solventum Corporation | $26.62 | 2025 | Prevena |
| Pacira Pharmaceuticals Incorporated | $23.44 | 2023 | Exparel |
| Evofem Biosciences, INC. | $23.31 | 2022 | |
| Radius Health, INC. | $20.95 | 2024 | |
| Hologic Sales and Service, LLC | $17.41 | 2024 | Discovery Ci, 3dimensions |
| Scynexis, INC. | $15.85 | 2022 | |
| Endo Pharmaceuticals INC. | $15.10 | 2022 | |
| Minerva Surgical, INC | $14.18 | 2023 | |
| Avion Pharmaceuticals | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanny Cortes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.